Constitutive expression of B7-1 (CD80) on mouse keratinocytes does not prevent development of chemically induced skin papillomas and carcinomas

Journal of Immunology

Volumn 156, Issue 9, 1996, Pages 3382-3388

  Williams, Ifor R ^a   Ort, Richard J ^a   Daley, Douglas ^a   Manning, Lisa ^a   Karaoli, Themis ^a   Barnhill, Raymond L ^a   Kupper, Thomas S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ALLOANTIGEN; B7 ANTIGEN; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; KERATINOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOMA; SKIN PAPILLOMA; TRANSGENIC MOUSE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD80; CARCINOMA; CARCINOMA, SQUAMOUS CELL; FEMALE; FLOW CYTOMETRY; ISOANTIGENS; KERATINOCYTES; MALE; MICE; MICE, TRANSGENIC; PAPILLOMA; SKIN NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0029886525     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Schwartz, R. H. 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71: 1065.
2. Chen, L., P. S. Linsley, and K. E. Hellström. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14:483.
3. Ostrand-Rosenberg, S. 1994. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr. Opin. Immunol. 6:722.
4. Guinan, E. C., J. G. Gribben, V. A. Boussiotis, G. J. Freeman, and L. M. Nadler. 1994. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261.
5. Chen, L., S. Ashe, W. A. Brady, I. Hellström, K. E. Hellström, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
6. + T cells by B7-transfected melanoma cells. Science 259:368.
7. Baskar, S., S. Ostrand-Rosenberg, N. Nabavi, L. M. Nadler, G. J. Freeman, and L. H. Glimcher. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci USA 90:5687.
8. Ramarathinam, L., M. Castle, Y. Wu, and Y. Liu. 1994. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179:1205.
9. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellström, and K. E. Hellström. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
10. Matulonis, U. A., C. Dosiou, C. Lamont, G. J. Freeman, P. Mauch, L. M. Nadler, and J. D. Griffin. 1995. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85:2507.
11. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181:619.
12. Chen, L., P. McGowan, S. Ashe, J. V. Johnston, I. Hellström, and K. E. Hellström. 1995. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res. 54:5420.
13. Hodge, J. W., S. Abrams, J. Schlom, and J. A. Kantor. 1994. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 54:5552.
14. Yang, G., K. E. Hellström, I. Hellström, and L. Chen. 1995. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154:2794.
15. Matulonis, U., C. Dosiou, C. Lamont, G. Freeman, P. Mauch, L. M. Nadler, and J. D. Griffin. 1996. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156:1126.
16. Townsend, S. E., F. W. Su, J. M. Atherton, and J. P. Allison. 1994. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54:6477.
17. Wu, T.-C., A. Y. C. Huang, E. M. Jaffee, H. I. Levitsky, and D. M. Pardoll. 1995. A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182:1415.
18. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153: 421.
19. Culver, K. W., and R. M. Blaese. 1994. Gene therapy for cancer. Trends Gen. 10:174.
20. Fenton, R. T., M. Sznol, D. G. Luster, D. D. Taub, and D. L. Longo. 1995. A phase I trial of B7-transfected or parental lethally-irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. Hum. Gene Ther. 6:87.
21. Cavallo, F., A. Martin-Fontecha, M. Bellone, S. Heltai, E. Gatti, P. Tornaghi, M. Freschi, G. Forni, P. Dellabona, and G. Casorati. 1995. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol. 25:1154.
22. Boutwell, R. K. 1974. The function and mechanism of promoters of carcinogenesis. CRC Crit. Rev. Toxicol. 2:419.
23. Kemp, C. J., L. A. Donehower, A. Bradley, and A. Balmain. 1993. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74:813.
24. Williams, I. R., R. J. Ort, and T. S. Kupper. 1994. Keratinocyte expression of B7-1 in transgenic mice amplifies the primary immune response to cutaneous antigens. Proc. Natl. Acad. Sci. USA 91:12780.
25. Williams, I. R., and T. S. Kupper. 1994. Epidermal ICAM-1 expression is not a primary inducer of cutaneous inflammation in transgenic mice. Proc. Natl. Acad. Sci. USA 91:9710.
26. Hennings, H., A. B. Glick, D. T. Lowry, L. S. Krsmanovic, L. M. Sly, and S. H. Yuspa. 1993. FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin. Carcinogenesis 14:2353.
27. +-adenosine triphosphatase during mouse skin tumor progression. Am. J. Path. 140:1179.
28. Bates, R. R. 1968. Sex hormones and skin tumorigenesis. I. Effect of the estrous cycle and castration on tumorigenesis by 7,12-dimethylbenz[a]-anthracene. J. Natl. Cancer Inst. 41:559.
29. Taketo, M., A. C. Schroeder, L. E. Mobraaten, K. B. Gunning, G. Hanten, R. R. Fox, T. H. Roderick, C. L. Stewart, F. Lilly, C. T. Hansen, and P. A. Ovetbeek. 1991. FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc. Natl. Acad. Sci. USA 88:2065.
30. Browning, M. J., and W. F. Bodmer. 1992. MHC antigens and cancer: implications for T-cell surveillance. Curr. Opin. Immunol. 4:613.
31. Chen, Z., S. I. Rosten, E. M. Lord, and A. A. Gaspari. 1993. Murine Pam 212 cutaneous squamous cell carcinoma is nonimmunogenic in normal syngeneic hosts and resistant to immune effector mechanisms. Reg. Immunol. 5:285.
32. Murray, M. J., L. D. Lauer, M. I. Luster, R. W. Luebke, D. O. Adams, and J. H. Dean. 1985. Correlation of murine susceptibility to tumor, parasite and bacterial challenge with altered cell-mediated immunity following systemic exposure to the tumor promoter phorbol myristate acetate. Int. J. Immunopharmacol. 7:491.
33. Green, J. M., P. J. Noel, A. T. Sperling, T. L. Walunas, G. S. Gray, J. A. Bluestone, and C. B. Thompson. 1994. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1:501.
34. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. S. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.
35. Sethna, M. P., L. van Parijs, A. H. Sharpe, A. K. Abbas, and G. J. Freeman. 1994. A negative regulatory function of B7 revealed in B7-1 transgenic mice. Immunity 1:415.
36. Krummel, M. F., and J. P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:459.
37. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985.
38. Nowell, P. C. 1995. Mechanisms of tumor progression. Cancer Res. 46:2203.
39. Murphy, E. E., G. Terres, S. E. Macatonia, C. S. Hsieh, J. Mattson, L. Lanier, M. Wysocka, G. Trinchieri, K. Murphy, and A. O'Garra. 1994. B7 and interleukin 12 cooperate for proliferation and interferon γ production by mouse T helper clones that are unresponsive to B7 costimulation. J. Exp. Med. 280:223.
40. Kubin, M., M. Kamoun, and G. Trinchieri. 1994. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J. Exp. Med. 180:211.
41. Gajewski, T. F., J.-C. Renauld, A. Van Pel, and T. Boon. 1995. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine anthumor cytolytic T lymphocytes in vitro. J. Immunol. 154:5637.
42. Cayeux, S., C. Beck, A. Aicher, B. Dorken, and T. Blankenstein. 1995. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur. J. Immunol. 25: 2325.
43. Yang, N.-S., and W. H. Sun. 1995. Gene gun and other non-viral approaches for cancer gene therapy. Nature Med. 1:481.